Docetaxel-Based Preoperative Chemoradiation in Localized Gastric Cancer: Impact of Pathological Complete Response on Patient Outcome

Rostom, Yousri; Zaghloul, Hala; Khedr, Gehan; Elshazly, Walid Galal; Abdallah, Dina

doi:10.1007/s12029-012-9449-3

Cited by 5 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can cause the disruption of cellular fuction via G2/M arrest (10). Many studies have reported that docetaxel-based CRT is tolerable and effective in ESCC patients receiving definite or preoperative CRT (11–13). Thus, taxotere-based CRT regimens were frequently used in these patients.…”

Section: Introductionmentioning

confidence: 99%

Long-term Clinical Outcome of Intensity-modulated Radiation Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Yang

Lü

et al. 2015

Tumori

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Long-term Clinical Outcome of Intensity-modulated Radiation Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Yang

Lü

et al. 2015

Tumori

View full text Add to dashboard Cite

show abstract

“…Compared with its use in EGJ and cardia cancers, the use of NCRT for noncardia gastric cancer is less validated due to the lack of phase III randomized controlled trials. Evidence from mostly uncontrolled studies [ 13 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 ] indicates that NCRT led to R0 resection and pCR rates of approximately 70–80% and approximately 20–25%, respectively. A review of the performances of NCRT and other modalities is presented as follows.…”

Section: Ncrt For Locally Advanced Resectable Noncardia Gastric Cancermentioning

confidence: 99%

Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer: Where Are We at?

Yeh

Tsai

et al. 2022

Cancers

View full text Add to dashboard Cite

Locally advanced gastric cancer (LAGC) has a poor prognosis with surgical resection alone, and neoadjuvant treatment has been recommended to improve surgical and oncological outcomes. Although neoadjuvant chemotherapy has been established to be effective for LAGC, the role of neoadjuvant chemoradiotherapy (NCRT) remains under investigation. Clinical experience and research evidence on esophagogastric junction adenocarcinoma (e.g., cardia gastric cancers) indicate that the likelihood of achieving sustainable local control is higher through NCRT than through resection alone. Furthermore, NCRT also has an acceptable treatment-related toxicity and adverse event profile. In particular, it increases the likelihood of achieving an R0 resection and a pathological complete response (pCR). Moreover, NCRT results in higher overall and recurrence-free survival rates than surgery alone; however, evidence on the survival benefits of NCRT versus neoadjuvant chemotherapy (NCT) remains conflicting. For noncardia gastric cancer, the efficacy of NCRT has mostly been reported in retrospective studies, and several large clinical trials are ongoing. Consequently, NCRT might play a more essential role in unresectable LAGC, for which NCT alone may not be adequate to attain disease control. The continual improvements in systemic treatments, radiotherapy techniques, and emerging biomarkers can also lead to improved personalized therapy for NCRT. To elucidate the contributions of NCRT to gastric cancer treatment in the future, the efficacy, potential toxicity, predictive biomarkers, and clinical considerations for implementing NCRT in different types of LAGC were reviewed.

show abstract

Gastric Cancer

Leong¹

2013

Decision Tools for Radiation Oncology

View full text Add to dashboard Cite

Docetaxel-Based Preoperative Chemoradiation in Localized Gastric Cancer: Impact of Pathological Complete Response on Patient Outcome

Abstract: Docetaxel-based chemoradiotherapy in localized gastric adenocarcinoma patients resulted in 24 % path CR and was not associated with a higher percentage of postoperative complications. A well-designed randomized controlled trial is mandatory to further endorse this evolving approach.

Cited by 5 publications

References 24 publications

Long-term Clinical Outcome of Intensity-modulated Radiation Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Long-term Clinical Outcome of Intensity-modulated Radiation Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer: Where Are We at?

Gastric Cancer

Contact Info

Product

Resources

About